PMC7242210_01
Chest computed tomography scan and x-rays of patient 1 (A), patient 2 (B), and patient 3 (C) before and after peginterferon alfa 2a.
gr1.jpg
PMC7242210_03_gr1.jpg
fig0005
A CT scan of the chest was done and showed bilateral ground glass opacities, with distribution more noted in the lower lobes (Fig. 1C). The chest X-ray showed unchanged infiltrates on March 28 (hospital day 6). (Fig. 1C).
PMC7242210_02
Chest computed tomography scan and x-rays of patient 1 (A), patient 2 (B), and patient 3 (C) before and after peginterferon alfa 2a.
gr1.jpg
PMC7242210_03_gr1.jpg
fig0005
A CT scan of the chest was done and showed bilateral ground glass opacities, with distribution more noted in the lower lobes (Fig. 1C). The chest X-ray showed unchanged infiltrates on March 28 (hospital day 6). (Fig. 1C).
PMC7242210_03
Chest computed tomography scan and x-rays of patient 1 (A), patient 2 (B), and patient 3 (C) before and after peginterferon alfa 2a.
gr1.jpg
PMC7242210_03_gr1.jpg
fig0005
A CT scan of the chest was done and showed bilateral ground glass opacities, with distribution more noted in the lower lobes (Fig. 1C). The chest X-ray showed unchanged infiltrates on March 28 (hospital day 6). (Fig. 1C).